Overview

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Status:
Recruiting

Trial end date:
2027-08-26

Target enrollment:

Participant gender:

Summary

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Phase:

Phase 3

Details

Lead Sponsor:

OncoQuest Pharmaceuticals Inc.

Collaborators:

Gynecologic Oncology Group
Iqvia Pty Ltd

Treatments:

Carboplatin
Oregovomab
Paclitaxel